Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructi
Beyond pulmonary complications, COPD presents with extrapulmonary manifestations including reduced cognitive, cardiovascular, and muscle function. While exercise training is the cornerstone in the non-pharmacological treatment of COPD, there is a need for new exercise training methods. The COPD-HIIT trial intend to inv
| Condition(s) | COPD, Healthy Controls |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Beyond pulmonary complications, COPD presents with extrapulmonary manifestations including reduced cognitive, cardiovascular, and muscle function. While exercise training is the cornerstone in the non-pharmacological treatment of COPD, there is a need for new exercise training methods. The COPD-HIIT trial intend to investigate the effects and mechanisms of 12 weeks supramaximal high-intensity interval-training (HIIT) compared to moderate intensive continous training (MICT) in people with COPD and matched healthy controls on important clinical outcomes. The trial also intends to compare the effects of 24 months of exercise training (supramaximal HIIT or MICT) to usual care in people with COPD on brain health, cardiorespiratory fitness and muscle power; in people with COPD. |
| Who can participate | The inclusion criteria are: 1. 60 years of age or older 2. Independent in activities of daily living 3. For people with COPD: Symptomatic (COPD assessment test \[CAT\] ≥10 or modified Medical Research Council dyspnea scale \[mMRC\] ≥2) or not being regularly physically active at a moderate or high intensity over the last year defined as not meeting WHO requirements for physical activity. 4. For people with COPD: Post-bronchodilator spirometry confirmed COPD diagnosis (forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio \< 0.70). 5. For healthy controls: Normal lung function The exclusion criteria are: 1. Movement related conditions, cardiovascular, neuromuscular, metabolic, skeletal and/or rheumatic conditions and diseases that are unstable and/or prohibits e |
| Ages | 60 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Umeå University |
| Locations | Hasselt, Diepenbeek, Belgium; Umeå, Sweden |
| Start date | 2023-11-09 |
| NCT ID | NCT06068322 |
| Official listing | https://clinicaltrials.gov/study/NCT06068322 |